/EYEN

EYEN Stock - Eyenovia, Inc.

Q: What is the analyst price target for EYEN?

Analyst price target information is not currently available for EYEN.

Q: What is EYEN's market cap?

Market capitalization information is not currently available for EYEN.

Healthcare|Biotechnology|NASDAQ

$7.56+3.99%

+$0.29 (+3.99%) • Oct 20

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $8.32

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for EYEN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.00

52W High$124.80

52W Low$0.85

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$57,336	$3,787	N/A	$14.00M	$2.00M
Gross Profit	$-3,869,892	N/A	$-307,430	$12.40M	$1.20M
Gross Margin	-6749.5%	0.0%	N/A	88.6%	60.0%
Operating Income	$-48,738,225	$-25,406,446	$-26,911,515	$-12,903,683	$-19,779,225
Net Income	$-49,818,433	$-27,261,096	$-27,730,741	$-12,991,763	$-19,691,494
Net Margin	-86888.6%	-719859.9%	N/A	-92.8%	-984.6%
EPS	$-59.81	$-0.66	$-0.82	$-0.49	$-0.94

Company Overview

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

100%

Sell / Underperform

Analyst Consensus🔴 Bearish

0 Bullish1 Neutral/Bearish

Price Targets

Average Target

↓ 73.5% Downside

Now

Low

Average

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
November 18th 2024	H.C. Wainwright	Downgrade	Neutral	$2← $12

Earnings History & Surprises

EYEN

Beat Rate

60%

Last 20 quarters

Avg Surprise

-220.4%

EPS vs Estimate

Beats / Misses

12/7

1 met exactly

Latest EPS

$0.23

Q4 2025

EPS Surprise History

Q2 24

-5.9%

$-0.18vs$-0.17

Q2 24

0.0%

$-14.40vs$-14.40

Q3 24

-5.9%

$-14.40vs$-13.60

Q4 24

+15.4%

$-8.80vs$-10.40

Q1 25

-80.0%

$-14.40vs$-8.00

Q2 25

+83.4%

$-1.59vs$-9.60

Q3 25

-100.0%

$-14.40vs$-7.20

Q4 25

+103.2%

$0.23vs$-7.20

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 13, 2025	$-7.20	$0.23	+103.2%	✓ BEAT
Q3 2025	Aug 11, 2025	$-7.20	$-14.40	-100.0%	✗ MISS
Q2 2025	May 19, 2025	$-9.60	$-1.59	+83.4%	✓ BEAT
Q1 2025	Mar 31, 2025	$-8.00	$-14.40	-80.0%	✗ MISS
Q4 2024	Nov 12, 2024	$-10.40	$-8.80	+15.4%	✓ BEAT
Q3 2024	Aug 12, 2024	$-13.60	$-14.40	-5.9%	✗ MISS
Q2 2024	May 15, 2024	$-14.40	$-14.40	0.0%	= MET
Q2 2024	Apr 4, 2024	$-0.17	$-0.18	-5.9%	✗ MISS
Q4 2023	Nov 13, 2023	$-15.20	$-14.40	+5.3%	✓ BEAT
Q3 2023	Aug 10, 2023	$-16.00	$-12.80	+20.0%	✓ BEAT
Q2 2023	May 11, 2023	$-15.20	$-12.00	+21.1%	✓ BEAT
Q1 2023	Mar 30, 2023	$-16.80	$-13.60	+19.0%	✓ BEAT
Q4 2022	Nov 10, 2022	$-16.00	$-16.80	-5.0%	✗ MISS
Q3 2022	Aug 10, 2022	$-14.40	$-17.60	-22.2%	✗ MISS
Q2 2022	May 12, 2022	$-0.23	$-19.20	-8247.8%	✗ MISS
Q1 2022	Mar 28, 2022	$-0.22	$8.00	+3736.4%	✓ BEAT
Q4 2021	Nov 10, 2021	$-20.80	$-18.40	+11.5%	✓ BEAT
Q3 2021	Aug 11, 2021	$-19.20	$-15.20	+20.8%	✓ BEAT
Q2 2021	May 12, 2021	$-17.60	$-16.80	+4.5%	✓ BEAT
Q1 2021	Mar 25, 2021	$-16.80	$-13.60	+19.0%	✓ BEAT